Search

Your search keyword '"William Nealon"' showing total 17 results
Start Over Author "William Nealon"
17 results on '"William Nealon"'

3. Supplemental Figures from Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer

Author

David A. Tuveson, Steven Gallinger, Alexander Krasnitz, Jennifer Knox, Richard Moffitt, Julie M. Wilson, Sandra E. Fischer, Benjamin Hubert, Christopher R. Vakoc, Ellen Li, Kenneth H. Yu, Christopher L. Wolfgang, Allyson Ocean, Craig Devoe, James M. Crawford, Edward Kim, Faiyaz Notta, Grainne M. O'Kane, Michael A. Hollingsworth, Jonathan R. Brody, Paul M. Grandgenett, Jonathan M. Buscaglia, Dominick J. DiMaio, Jean L. Grem, Phyllis A. Gimotty, Jordan M. Winter, James D. Sullivan, William Nealon, Divyesh V. Sejpal, Peter Allen, Juan Carlos Bucobo, Maoxin Wu, Joseph Kim, Aaron Sasson, Brian M. Wolpin, Andrew J. Aguirre, Elizabeth Thompson, Ralph H. Hruban, Laura D. Wood, Hans Clevers, Christine A. Iacobuzio-Donahue, Gokce Askan, Nicolas LeComte, Else Driehuis, Laura Martello, Cinthya Y. Lowder, Austin B. Goetz, Rashesh Sanghvi, Minita Shah, Nicolas Robine, Kanika Arora, Molly Johnson, Jasmine C. Huynh, Ammar A. Javed, Randze Lerie D. Palmaira, Joseph F. LaComb, Michelle Ma, Hardik Patel, C. Megan Young, Koji Miyabayashi, Gun-Ho Jang, Robert E. Denroche, Richard A. Burkhart, Fieke E. M. Froeling, Tim D. D. Somerville, Astrid Deschênes, Dennis Plenker, Dannielle D. Engle, Pascal Belleau, and Hervé Tiriac

Abstract

Supplemental Figures

Published
2023

4. Table S3 from Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer

Author

David A. Tuveson, Steven Gallinger, Alexander Krasnitz, Jennifer Knox, Richard Moffitt, Julie M. Wilson, Sandra E. Fischer, Benjamin Hubert, Christopher R. Vakoc, Ellen Li, Kenneth H. Yu, Christopher L. Wolfgang, Allyson Ocean, Craig Devoe, James M. Crawford, Edward Kim, Faiyaz Notta, Grainne M. O'Kane, Michael A. Hollingsworth, Jonathan R. Brody, Paul M. Grandgenett, Jonathan M. Buscaglia, Dominick J. DiMaio, Jean L. Grem, Phyllis A. Gimotty, Jordan M. Winter, James D. Sullivan, William Nealon, Divyesh V. Sejpal, Peter Allen, Juan Carlos Bucobo, Maoxin Wu, Joseph Kim, Aaron Sasson, Brian M. Wolpin, Andrew J. Aguirre, Elizabeth Thompson, Ralph H. Hruban, Laura D. Wood, Hans Clevers, Christine A. Iacobuzio-Donahue, Gokce Askan, Nicolas LeComte, Else Driehuis, Laura Martello, Cinthya Y. Lowder, Austin B. Goetz, Rashesh Sanghvi, Minita Shah, Nicolas Robine, Kanika Arora, Molly Johnson, Jasmine C. Huynh, Ammar A. Javed, Randze Lerie D. Palmaira, Joseph F. LaComb, Michelle Ma, Hardik Patel, C. Megan Young, Koji Miyabayashi, Gun-Ho Jang, Robert E. Denroche, Richard A. Burkhart, Fieke E. M. Froeling, Tim D. D. Somerville, Astrid Deschênes, Dennis Plenker, Dannielle D. Engle, Pascal Belleau, and Hervé Tiriac

Abstract

Table S3

Published
2023

5. Table S2 from Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer

Author

David A. Tuveson, Steven Gallinger, Alexander Krasnitz, Jennifer Knox, Richard Moffitt, Julie M. Wilson, Sandra E. Fischer, Benjamin Hubert, Christopher R. Vakoc, Ellen Li, Kenneth H. Yu, Christopher L. Wolfgang, Allyson Ocean, Craig Devoe, James M. Crawford, Edward Kim, Faiyaz Notta, Grainne M. O'Kane, Michael A. Hollingsworth, Jonathan R. Brody, Paul M. Grandgenett, Jonathan M. Buscaglia, Dominick J. DiMaio, Jean L. Grem, Phyllis A. Gimotty, Jordan M. Winter, James D. Sullivan, William Nealon, Divyesh V. Sejpal, Peter Allen, Juan Carlos Bucobo, Maoxin Wu, Joseph Kim, Aaron Sasson, Brian M. Wolpin, Andrew J. Aguirre, Elizabeth Thompson, Ralph H. Hruban, Laura D. Wood, Hans Clevers, Christine A. Iacobuzio-Donahue, Gokce Askan, Nicolas LeComte, Else Driehuis, Laura Martello, Cinthya Y. Lowder, Austin B. Goetz, Rashesh Sanghvi, Minita Shah, Nicolas Robine, Kanika Arora, Molly Johnson, Jasmine C. Huynh, Ammar A. Javed, Randze Lerie D. Palmaira, Joseph F. LaComb, Michelle Ma, Hardik Patel, C. Megan Young, Koji Miyabayashi, Gun-Ho Jang, Robert E. Denroche, Richard A. Burkhart, Fieke E. M. Froeling, Tim D. D. Somerville, Astrid Deschênes, Dennis Plenker, Dannielle D. Engle, Pascal Belleau, and Hervé Tiriac

Abstract

Table S2

Published
2023

6. Table S1 from Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer

Author

David A. Tuveson, Steven Gallinger, Alexander Krasnitz, Jennifer Knox, Richard Moffitt, Julie M. Wilson, Sandra E. Fischer, Benjamin Hubert, Christopher R. Vakoc, Ellen Li, Kenneth H. Yu, Christopher L. Wolfgang, Allyson Ocean, Craig Devoe, James M. Crawford, Edward Kim, Faiyaz Notta, Grainne M. O'Kane, Michael A. Hollingsworth, Jonathan R. Brody, Paul M. Grandgenett, Jonathan M. Buscaglia, Dominick J. DiMaio, Jean L. Grem, Phyllis A. Gimotty, Jordan M. Winter, James D. Sullivan, William Nealon, Divyesh V. Sejpal, Peter Allen, Juan Carlos Bucobo, Maoxin Wu, Joseph Kim, Aaron Sasson, Brian M. Wolpin, Andrew J. Aguirre, Elizabeth Thompson, Ralph H. Hruban, Laura D. Wood, Hans Clevers, Christine A. Iacobuzio-Donahue, Gokce Askan, Nicolas LeComte, Else Driehuis, Laura Martello, Cinthya Y. Lowder, Austin B. Goetz, Rashesh Sanghvi, Minita Shah, Nicolas Robine, Kanika Arora, Molly Johnson, Jasmine C. Huynh, Ammar A. Javed, Randze Lerie D. Palmaira, Joseph F. LaComb, Michelle Ma, Hardik Patel, C. Megan Young, Koji Miyabayashi, Gun-Ho Jang, Robert E. Denroche, Richard A. Burkhart, Fieke E. M. Froeling, Tim D. D. Somerville, Astrid Deschênes, Dennis Plenker, Dannielle D. Engle, Pascal Belleau, and Hervé Tiriac

Abstract

Table S1

Published
2023

7. Table S5 from Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer

Author

David A. Tuveson, Steven Gallinger, Alexander Krasnitz, Jennifer Knox, Richard Moffitt, Julie M. Wilson, Sandra E. Fischer, Benjamin Hubert, Christopher R. Vakoc, Ellen Li, Kenneth H. Yu, Christopher L. Wolfgang, Allyson Ocean, Craig Devoe, James M. Crawford, Edward Kim, Faiyaz Notta, Grainne M. O'Kane, Michael A. Hollingsworth, Jonathan R. Brody, Paul M. Grandgenett, Jonathan M. Buscaglia, Dominick J. DiMaio, Jean L. Grem, Phyllis A. Gimotty, Jordan M. Winter, James D. Sullivan, William Nealon, Divyesh V. Sejpal, Peter Allen, Juan Carlos Bucobo, Maoxin Wu, Joseph Kim, Aaron Sasson, Brian M. Wolpin, Andrew J. Aguirre, Elizabeth Thompson, Ralph H. Hruban, Laura D. Wood, Hans Clevers, Christine A. Iacobuzio-Donahue, Gokce Askan, Nicolas LeComte, Else Driehuis, Laura Martello, Cinthya Y. Lowder, Austin B. Goetz, Rashesh Sanghvi, Minita Shah, Nicolas Robine, Kanika Arora, Molly Johnson, Jasmine C. Huynh, Ammar A. Javed, Randze Lerie D. Palmaira, Joseph F. LaComb, Michelle Ma, Hardik Patel, C. Megan Young, Koji Miyabayashi, Gun-Ho Jang, Robert E. Denroche, Richard A. Burkhart, Fieke E. M. Froeling, Tim D. D. Somerville, Astrid Deschênes, Dennis Plenker, Dannielle D. Engle, Pascal Belleau, and Hervé Tiriac

Abstract

Table S5

Published
2023

8. Table S4 from Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer

Author

David A. Tuveson, Steven Gallinger, Alexander Krasnitz, Jennifer Knox, Richard Moffitt, Julie M. Wilson, Sandra E. Fischer, Benjamin Hubert, Christopher R. Vakoc, Ellen Li, Kenneth H. Yu, Christopher L. Wolfgang, Allyson Ocean, Craig Devoe, James M. Crawford, Edward Kim, Faiyaz Notta, Grainne M. O'Kane, Michael A. Hollingsworth, Jonathan R. Brody, Paul M. Grandgenett, Jonathan M. Buscaglia, Dominick J. DiMaio, Jean L. Grem, Phyllis A. Gimotty, Jordan M. Winter, James D. Sullivan, William Nealon, Divyesh V. Sejpal, Peter Allen, Juan Carlos Bucobo, Maoxin Wu, Joseph Kim, Aaron Sasson, Brian M. Wolpin, Andrew J. Aguirre, Elizabeth Thompson, Ralph H. Hruban, Laura D. Wood, Hans Clevers, Christine A. Iacobuzio-Donahue, Gokce Askan, Nicolas LeComte, Else Driehuis, Laura Martello, Cinthya Y. Lowder, Austin B. Goetz, Rashesh Sanghvi, Minita Shah, Nicolas Robine, Kanika Arora, Molly Johnson, Jasmine C. Huynh, Ammar A. Javed, Randze Lerie D. Palmaira, Joseph F. LaComb, Michelle Ma, Hardik Patel, C. Megan Young, Koji Miyabayashi, Gun-Ho Jang, Robert E. Denroche, Richard A. Burkhart, Fieke E. M. Froeling, Tim D. D. Somerville, Astrid Deschênes, Dennis Plenker, Dannielle D. Engle, Pascal Belleau, and Hervé Tiriac

Abstract

Table S4

Published
2023

9. Supplemental Table Legends from Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer

Author

David A. Tuveson, Steven Gallinger, Alexander Krasnitz, Jennifer Knox, Richard Moffitt, Julie M. Wilson, Sandra E. Fischer, Benjamin Hubert, Christopher R. Vakoc, Ellen Li, Kenneth H. Yu, Christopher L. Wolfgang, Allyson Ocean, Craig Devoe, James M. Crawford, Edward Kim, Faiyaz Notta, Grainne M. O'Kane, Michael A. Hollingsworth, Jonathan R. Brody, Paul M. Grandgenett, Jonathan M. Buscaglia, Dominick J. DiMaio, Jean L. Grem, Phyllis A. Gimotty, Jordan M. Winter, James D. Sullivan, William Nealon, Divyesh V. Sejpal, Peter Allen, Juan Carlos Bucobo, Maoxin Wu, Joseph Kim, Aaron Sasson, Brian M. Wolpin, Andrew J. Aguirre, Elizabeth Thompson, Ralph H. Hruban, Laura D. Wood, Hans Clevers, Christine A. Iacobuzio-Donahue, Gokce Askan, Nicolas LeComte, Else Driehuis, Laura Martello, Cinthya Y. Lowder, Austin B. Goetz, Rashesh Sanghvi, Minita Shah, Nicolas Robine, Kanika Arora, Molly Johnson, Jasmine C. Huynh, Ammar A. Javed, Randze Lerie D. Palmaira, Joseph F. LaComb, Michelle Ma, Hardik Patel, C. Megan Young, Koji Miyabayashi, Gun-Ho Jang, Robert E. Denroche, Richard A. Burkhart, Fieke E. M. Froeling, Tim D. D. Somerville, Astrid Deschênes, Dennis Plenker, Dannielle D. Engle, Pascal Belleau, and Hervé Tiriac

Abstract

Supplemental Table Legends

Published
2023

10. Ampullary Neuroendocrine Tumors: Insight into a Rare Histology

Author

Sandeep Anantha, Oliver Standring, Grace Wu, Danielle K. DePeralta, Martin S. Karpeh, William Nealon, Samantha M. Ruff, Elliot Newman, Matthew J. Weiss, Gary B. Deutsch, and Anna Levy

Subjects
medicine.medical_specialty, business.industry, Proportional hazards model, Hazard ratio, Cancer, Histology, Neuroendocrine tumors, medicine.disease, Gastroenterology, medicine.anatomical_structure, Oncology, Surgical oncology, Internal medicine, medicine, Surgery, Lymph, business, Lymph node
Abstract

Ampullary neuroendocrine tumors (NETs) make up

Published
2021

11. Rare, long-term complication after pancreatoduodenectomy—a case report of cecal volvulus

Author

Danielle K. DePeralta, William Nealon, Michelle P. Kallis, Anna Levy, Caroline Maloney, Matthew J. Weiss, and Colleen P Nofi

Subjects
medicine.medical_specialty, Cecal volvulus, AcademicSubjects/MED00910, business.industry, medicine.medical_treatment, General surgery, Case Report, medicine.disease, Pancreaticoduodenectomy, Right Colectomy, medicine, Ascending colon, Adenocarcinoma, Surgery, Surgical emergency, Presentation (obstetrics), business, Complication, jscrep/040
Abstract

Complications after pancreatoduodenectomy are common, and range widely in timing of presentation, relation to pancreatobiliary pathology, and necessity of operative intervention. We present a case of a 74-year-old male with history of pancreatoduodenectomy for pancreatic adenocarcinoma who presented 11 months after index operation with cecal volvulus and required emergent right hemicolectomy. Prior history of pancreatoduodenectomy with mobilization of the right colon likely predisposed him to development of this surgical emergency. Patients have altered gastrointestinal anatomy after pancreatoduodenectomy and special care is necessary to protect the afferent biliopancreatic limb during intraoperative exploration, and particularly if right colectomy is necessary.

Published
2021

12. Ampullary Neuroendocrine Tumors: Insight into a Rare Histology

Author

Samantha M, Ruff, Oliver, Standring, Grace, Wu, Anna, Levy, Sandeep, Anantha, Elliot, Newman, Martin S, Karpeh, William, Nealon, Gary B, Deutsch, Matthew J, Weiss, and Danielle K, DePeralta

Subjects
Pancreatic Neoplasms, Neuroendocrine Tumors, Duodenal Neoplasms, Common Bile Duct Neoplasms, Humans, Proportional Hazards Models
Abstract

Ampullary neuroendocrine tumors (NETs) make up 1% of all gastroenteropancreatic NETs, and information is limited to case series. This study compares patients with ampullary, duodenal, and pancreatic head NETs.The National Cancer Database (2004-2016) was queried for patients with ampullary, duodenal, and pancreatic head NETs. Survival was evaluated using Kaplan-Meier analysis and Cox regression.Overall, 872, 9692, and 6561 patients were identified with ampullary, duodenal, and pancreatic head NETs, respectively. Patients with ampullary NETs had more grade 3 tumors (n = 149, 17%) than patients with duodenal (n = 197, 2%) or pancreatic head (n = 740, 11%) NETs. Patients with ampullary NETs had more positive lymph nodes (n = 297, 34%) than patients with duodenal (n = 950, 10%) or pancreatic head (n = 1513, 23%) NETs. On multivariable analysis for patients with ampullary NETs, age (hazard ratio [HR] 1.03, p 0.0001), Charlson-Deyo score of 2 (HR 2.3, p = 0.001) or ≥3 (HR 2.9, p = 0.013), grade 2 (HR 1.9, p = 0.007) or grade 3 tumors (HR 4.0, p 0.0001), and metastatic disease (HR 2.0, p = 0.001) were associated with decreased survival. At 5 years, the overall survival (OS) for patients with ampullary, duodenal, and pancreatic head NETs was 59%, 71%, and 50%, respectively (p 0.0001), whereas the 5-year OS for patients with ampullary, duodenal, and pancreatic head NETs who underwent surgery was 62%, 78%, and 76%, respectively (p 0.0001).Ampullary NETs were more likely to present with high-grade tumors and lymph node metastases. Based on the clinicopathologic and survival data, ampullary NETs have a unique underlying biology compared with duodenal and pancreatic head NETs.

Published
2021

13. ASO Visual Abstract: Ampullary Neuroendocrine Tumors—Insight into a Rare Histology

Author

Elliot Newman, Oliver Standring, William Nealon, Grace Wu, Sandeep Anantha, Samantha M. Ruff, Anna Levy, Matthew J. Weiss, Danielle K. DePeralta, Martin S. Karpeh, and Gary B. Deutsch

Subjects
Oncology, medicine.medical_specialty, business.industry, Histology, Neuroendocrine tumors, medicine.disease, Pancreatic head, Rare tumor, Surgical oncology, Internal medicine, medicine, Overall survival, Surgery, National database, business
Abstract

Ampullary neuroendocrine tumors (NETs) make up

Published
2021

14. The timing and the dose of advanced care planning in patients with resectable pancreatic cancer: Who makes the call?

Author

Grace Wu, Dina Moumin, Edith Burns, Danielle K. DePeralta, Lyudmyla Demyan, Gary B. Deutsch, Matthew J. Weiss, Joseph M. Herman, and William Nealon

Subjects
Resectable Pancreatic Cancer, Oncology, Cancer Research, medicine.medical_specialty, Pancreatic ductal adenocarcinoma, business.industry, Resection, 03 medical and health sciences, 0302 clinical medicine, 030220 oncology & carcinogenesis, Internal medicine, Medicine, In patient, business, 030215 immunology
Abstract

397 Background:The timing and the extent of Advanced Care Planning (ACP) in patients with pancreatic ductal adenocarcinoma (PDAC) undergoing curative-intent resection are generally dictated by the surgeon performing the operation. The aim of this study is to evaluate surgeons’ insights, perceptions, and biases regarding preoperative ACP. We hypothesize that many surgeons harbor significant reservations about extensive preoperative ACP. Methods:A qualitative investigation using 1:1 interviews with 40 open-ended questions were conducted with convenience sample. Data accrual continued until theme saturation was achieved. Grounded theory approach was used for data coding and analysis. Results:A total of 10 interviews were conducted with expert pancreatic surgeons from 6 medical centers—6 males and 4 females. The median number of years in practice was 15 (IQR 13-30) and the median number of pancreatic cancer cases performed per year was 52 (IQR 39-75). During preoperative counseling all surgeons discuss the possibility of recurrence and postoperative complications but attempt to motivate patients by emphasizing hope, optimism, and fact that surgery offers the only opportunity for cure. 90% of surgeons report no formal training in ACP. All surgeons report comfort with end of life conversations when death is imminent, but most lack experience with in-depth preoperative ACP. All surgeons emphasized that ACP should be led by a physician that both knows the patient well and understands the complexity of PDAC management. All surgeons recognized potential benefits of ACP, including delivery of goal-concordant care (60%), increased prognostic awareness (40%), and better life planning (40%). 50% report discussing in-depth ACP related to perioperative complications, but not long-term oncologic outcome. 80% of surgeons report that they actively steer away from in-depth ACP during preoperative counseling. Barriers to in-depth ACP reported by surgeons include taking away hope (70%), lack of time (50%) and concern for sending “mixed messages” (50%). Further, 50% of surgeons perceived that extensive preoperative ACP is not appropriate for patients with PDAC undergoing curative-intent resection. Most surgeons (60%) believe that ACP should occur as a process throughout the disease and in-depth discussions were more appropriate during postoperative visits (30%) and/or recurrence (60%). Conclusions:Despite recognizing potential benefits, most pancreatic surgeons report actively avoiding in-depth ACP conversations prior to curative-intent surgery. Surgeons had difficulty articulating the best time for ACP and felt that ACP should occur as a continuum throughout the course of treatment, with the depth of the discussion echoing the disease progression and patients’ readiness for such conversation. Future studies could evaluate patients’ perspective on the timing and the dose of ACP.

Published
2021

15. Safety and efficacy of biweekly gemcitabine in combination with capecitabine (GemCap) in elderly and frail patients (pts) with resected pancreatic cancer (PC)

Author

Nausheen Hakim, Antonia Maloney, Jyothi Jose, Linda Moriarty, Wasif M. Saif, Jeffrey Chi, Danielle K. DePeralta, Gary B. Deutsch, Melissa H Smith, Sandeep Anantha, Arvind Rishi, Hasan Rehman, Elliot Newman, Gene F. Coppa, and William Nealon

Subjects
Oncology, Cancer Research, medicine.medical_specialty, business.industry, medicine.disease, Gemcitabine, Capecitabine, Survival benefit, Pancreatic cancer, Internal medicine, medicine, business, medicine.drug
Abstract

4628 Background: ESPAC-4 study showed that GemCap conferred a survival benefit over gemcitabine monotherapy in resected PC patients. ESPAC-4 included patients with median age of 65 years (37-81) and ECOG performance status (PS) of 0 (43%), 1 (54%) and 2 (2%) who received a median cumulative dose of gemcitabine of 15,000 mg/m2, capecitabine. Here we present our experience with an adopted biweekly regimen of GemCap in patients who were ≥ 75 years and those who were deemed not suitable for ESPAC-4 regimen. Methods: Patients ≥ 75 years with resected PC, ECOG PS of 0-2 and no prior treatments were included. Patients were treated with a modified regimen of gemcitabine (1000-2000 mg/m2) every 2 weeks and capecitabine (800-1000 mg/m2) day 1-7 every 2 weeks. Patients were evaluated for progression-free survival (PFS), overall survival (OS) and sites of recurrence. Toxicities were graded according to NCI CTCAE v5.0. Results: Thirty-five (22M, 13F) patients, ≥ 75 (median age 79) treated with biweekly Gem-Cap adjuvant treatment. 7 (28%) patients had ECOG PS of 1 and 28 (72%) had ECOG PS of 2. There were 5, 7 and 16 patients with stage I, II and III disease. Nine patients (25%) had R1 and 26 (75%) had R0 resection. The median PFS and OS were 8.0 months and 22.0 months. Nine (25%) had local recurrence, 21 (60%) had metastatic disease and 3 (8.6%) had NED. Two patients were lost to follow-up. The most frequent toxicities were grades 1-2 anemia (20%), thrombocytopenia (8%) and hand-foot syndrome (HFS) (10%). Grade ≥3 included diarrhea (4%) and HFS (1%) with no treatment-related discontinuations. Treatment compliance was 100%. Delays were necessary in 7% of cases and dose reduction was required in 4% of cases. There was no treatment related death. Conclusions: This schedule of biweekly GemCap regimen suggests an acceptable option in for elderly, frail patients with PC and warrants further exploration in patients not suitable for FOLFIRINOX, full dose GemCap or a clinical trial. This regimen required fewer dose reduction, omission or delays and allowed to administer pegylated-filgrastim. Previous studies have also shown decreased toxicity and equal efficacy of 7/7 schedule of capecitabine. Moreover, fewer visits to oncology and related expense do favor towards benefit. Additionally, this tolerable regimen is ideal to be combined with immunotherapy in clinical trials for this patient population.

Published
2020

16. 468: INTRAOPERATIVE USE OF REBOA BY A MULTIDISCIPLINARY TEAM FOR NONTRAUMATIC TORSO HEMORRHAGE

Author

Daniel Ohngemach, Maria Sfakianos, Andrew Lee, Eric J. Gandras, George Athanasatos, William Nealon, Bilge Kalyon, Danielle Aronowitz, Ujas Shah, Matthew Bank, and John J. Platz

Subjects
medicine.anatomical_structure, business.industry, medicine, Medical emergency, Torso, Critical Care and Intensive Care Medicine, medicine.disease, business, Multidisciplinary team
Published
2020

Catalog

Books, media, physical & digital resources
See catalog results